Pular para o conteúdo
Doenças metabólicas com epilepsia
ORPHA:166481PCDT · SUSDOENÇA RARA

Grupo de doenças raras caracterizadas por distúrbios metabólicos que levam ao desenvolvimento de epilepsia. Podem afetar o desenvolvimento neurológico e causar outros sintomas.

Última verificação: Fonte: verificadoEsboçohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

Mantido pelo Disease Twin86% com fonte · atualizado 04/06/2026Revisão médica pendente
Informacoes curadas por IA — podem conter imprecisoes

Visão geral

As doenças metabólicas com epilepsia são um grupo heterogêneo de condições hereditárias em que um distúrbio do metabolismo celular leva a crises epilépticas recorrentes. Essas doenças podem afetar diferentes vias metabólicas, como o metabolismo de aminoácidos, carboidratos, ácidos graxos ou organelas celulares, e a epilepsia é frequentemente um dos primeiros sinais da doença de base. O diagnóstico precoce é fundamental, pois algumas dessas condições podem responder a intervenções dietéticas ou medicamentosas específicas.[1]

Sinais e sintomas

Os sintomas variam amplamente conforme o tipo de erro inato do metabolismo, mas a epilepsia é o sintoma central e pode se manifestar como crises focais, generalizadas ou mioclônicas. Outros sinais comuns incluem atraso no desenvolvimento neuropsicomotor, regressão de marcos do desenvolvimento, hipotonia, letargia, vômitos recorrentes, acidose metabólica, hipoglicemia e alterações no nível de consciência. Em muitos casos, os sintomas podem ser desencadeados por jejum, infecções ou ingestão de certos alimentos.[1]

Causas genéticas

As doenças metabólicas com epilepsia são causadas por mutações em genes que codificam enzimas, transportadores ou proteínas envolvidas no metabolismo celular. Embora o gene específico varie conforme a doença, a herança é geralmente autossômica recessiva, mas padrões ligados ao X ou mitocondriais também podem ocorrer. O diagnóstico genético pode ser estabelecido por sequenciamento de painéis de genes metabólicos ou por sequenciamento do exoma.[1][2]

Diagnóstico

O diagnóstico é baseado na suspeita clínica (epilepsia de início precoce associada a outros sinais metabólicos), exames laboratoriais (dosagem de aminoácidos, ácidos orgânicos, acilcarnitinas, lactato, amônia, glicose, entre outros) e confirmação por teste genético molecular. A identificação da variante patogênica em um gene associado ao metabolismo é o padrão-ouro. O aconselhamento genético é recomendado para a família.[1][2]

Tratamento e manejo

O tratamento depende da doença metabólica específica e pode incluir dietas especiais (como dieta cetogênica, restrição de proteínas ou de certos carboidratos), suplementação de vitaminas ou cofatores (por exemplo, piridoxina, biotina, carnitina) e medicamentos anticrise. O manejo deve ser multidisciplinar, envolvendo neurologista, geneticista, nutricionista e outros especialistas. O objetivo é controlar as crises epilépticas e prevenir danos neurológicos progressivos.[1]

Prognóstico e qualidade de vida

O prognóstico varia amplamente conforme a doença metabólica específica, a idade de início, a gravidade do comprometimento neurológico e a precocidade do tratamento. Algumas condições respondem bem a intervenções dietéticas ou medicamentosas, permitindo controle das crises e desenvolvimento próximo do normal. Outras podem evoluir com deficiência intelectual, paralisia cerebral ou óbito precoce. O acompanhamento regular e o suporte multidisciplinar são essenciais para otimizar a qualidade de vida.[1]

Fontes numeradas em Referências.

Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.

💬
EM LINGUAGEM SIMPLES

As doenças metabólicas com epilepsia formam um grupo clínico que reúne diferentes condições metabólicas raras que causam crises epilépticas. Os sinais e os impactos no desenvolvimento variam amplamente conforme o tipo específico de erro inato do metabolismo presente no indivíduo. No Brasil, este grupo não possui uma diretriz exclusiva na lista oficial de PCDTs de doenças raras do Ministério da Saúde, sendo acompanhado pelas diretrizes gerais de epilepsia do SUS. Medicamentos como a lamotrigina contam com registro comercial na Anvisa para o controle de crises, cabendo à equipe médica definir a abordagem para cada caso.

📋
Informacoes curadas por IA — podem conter imprecisoes

Grupo de doenças raras caracterizadas por distúrbios metabólicos que levam ao desenvolvimento de epilepsia. Podem afetar o desenvolvimento neurológico e causar outros sintomas.

Medicamentos
11 com registro
LAMOTRIGINA, LAMITOR CD, FORLUT

Tem tratamento?

✓ 11 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
LAMOTRIGINALAMITOR CDFORLUTLAMOSYN CDLAMEZNEPILL�PTICOLAMICTAL
🏥
SUS: Cobertura parcialScore: 50%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1
Últimos 10 anos200publicações
Pico2025105 papers
Linha do tempo
2025Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doenças metabólicas com epilepsia

Centros de Referência SUS

21 centros habilitados pelo SUS para Doenças metabólicas com epilepsia

Centros para Doenças metabólicas com epilepsia

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology2026 Feb 13

Before diagnostic whole exome sequencing, monogenic/chromosomal developmental and epileptic encephalopathies (DEEs) were frequently misdiagnosed as mitochondrial disorders (MDs) with epilepsy, due to overlapping clinical and biochemical features. Assessing muscle functional assays in patients with a genetic diagnosis and epilepsy offers a unique opportunity to explore mitochondrial dysfunction in monogenic/chromosomal DEEs, in comparison to the mitochondrial dysfunction observed in genetically confirmed MDs. In this retrospective cohort study, clinical and biochemical data were extracted from patients suspected of MD with epilepsy who underwent muscle/fibroblast biopsy (2005-2015). Patients were classified into four groups based on the final diagnosis. Mitochondrial Disease Criteria scores were assigned. Statistical analyses were conducted using Fisher's exact, analysis of variance, and Kruskal-Wallis tests. Of 27 included participants, eleven (40.7%) had DEEs, four (14.8%) had genetically confirmed MDs, eight (29.6%) were suspected MD cases without genetic confirmation, and four (14.8%) had nonmitochondrial metabolic diseases. Mitochondrial dysfunction was common across all groups; 85% of participants met probable/definite Mitochondrial Disease Criteria, over 70% had elevated plasma lactate (>2.5 mmol/L), and 92% exhibited impaired adenosine triphosphate production. Surprisingly, moderate to severe complex dysfunction was observed in all groups except genetically confirmed MDs. Our findings indicate that mitochondrial dysfunction is prevalent in nonmitochondrial DEEs. Patients previously diagnosed with an MD based only on muscle/fibroblast biopsy may benefit from whole exome sequencing to identify genetic variants, for which targeted therapy may be available. Future research should explore whether treatment or prognosis of nonmitochondrial DEEs should be tailored to improve mitochondrial function.

#2

Molecular mechanisms underlying the ferroptosis-induced epileptiform activity in mouse cortical slices.

Frontiers in cellular neuroscience2026

Ferroptosis, a newly defined iron-dependent programmed cell death, characterized by excessive accumulation of lipid peroxides and reactive oxygen species, is involved in epilepsy, particularly in those forms resistant to drugs. In a previous study, we have demonstrated that exposure of mouse cortical slices to the ferroptosis inducer RSL-3, induces interictal epileptiform discharges. To investigate the mechanisms underlying ferroptosis-induced epileptic activity in RSL-3-treated cortical slices, we analysed the expression of the main contributors to ferroptosis susceptibility in cells. The expression of proteins involved in RSL-3 induced ferroptosis pathways were analysed on mouse cortical slices by Western blot and qRT-PCR. The epileptogenic response was investigated by electrophysiological patch clamp recordings, in current clamp mode, from layer 2/3 mouse cortical slices. In cortical neurons, the ferroptosis induction by RSL-3 was associated with a reduced expression of the GPX4/GSH redox pathway, responsible for the clearance of lipid peroxides, and an upregulation of 15-LOX, which promotes the formation of lipid peroxides. Furthermore, the cysteine/glutamate antiporter Xc-, a modulator of excitotoxicity in the brain, was up-regulated either after RSL-3-treatment or by incubating neurons with 4-HNE, the bioactive product of lipid peroxidation. Interestingly, 4-HNE was able to generate spontaneous interictal bursts. Our findings establish a direct link between lipid peroxidation and Xc- activity. These results suggest that the xCT antiporter may represent a promising therapeutic target for treating ferroptosis-mediated drug-resistant epilepsy.

#3

Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial.

BMJ open2026 Mar 11

Cerebral amyloid angiopathy (CAA) is caused by the accumulation of amyloid-beta (Aβ) in the cerebrovasculature. The glymphatic system is thought to be involved in the clearance of cerebral waste products, including Aβ. Stimulation of the glymphatic system through enhancing deep sleep with low-sodium oxybate (LXB) or inhibition of cortical spreading depolarisations via non-invasive vagus nerve stimulation (nVNS) could potentially increase clearance of Aβ and hence improve disease course. We will perform a pre-post trial to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA. A total of 60 participants, 30 with sporadic CAA and 30 with Dutch-type CAA, will be randomly assigned to receive either LXB, nVNS or both interventions, resulting in three groups (20 in each group: LXB, nVNS and both). The study spans 6 months, comprising a 3-month observational phase and a 3-month intervention phase. The primary outcome measure will be the morning levels of Aβ40 and Aβ42 in cerebrospinal fluid (CSF) before and after the intervention. We will assess possible disease progression with (non-)haemorrhagic imaging markers on 7-Tesla MRI at baseline, before and after intervention, as a secondary outcome. Additionally, the activity of the glymphatic system by means of fluid dynamics will be assessed with CSF-Selective T2-weighted Readout with Acceleration and Mobility encoding (CSF-STREAM) on 7-Tesla MRI. The study was reviewed and approved by the Medical Research Ethics Committee Leiden The Hague Delft (P23.100) on 8 April 2024. The first participant was enrolled on 27 March 2025. Study results will be published in peer-reviewed journals and presented at scientific conferences. Additionally, study updates and results will be shared with participants via our newsletter twice a year. EU CT number 2023-5 06 128-10-00, Universal Trial Number U1111-1295-1113, ClinicalTrials.gov NCT06421532.

#4

Molecular connectivity studies of cerebral glucose metabolism and blood flow: A scoping review.

Neuroscience and biobehavioral reviews2026 Mar 05

The brain's functional organization relies on neural, metabolic, and vascular interactions. Molecular neuroimaging offers powerful tools for assessing macroscale brain connectivity by capturing relationships between regional perfusion and glucose metabolism. This review summarizes molecular connectivity studies of cerebral blood flow (CBF) and metabolism, focusing on methodological approaches and key findings. A systematic search across MEDLINE, EMBASE, and Scopus identified studies employing radiotracers to examine brain perfusion or glucose metabolic connectivity. Data extraction focused on tracer type, connectivity methodology, population, and clinical relevance. Overall, 384 studies were included, covering healthy condition, dementia, movement disorders, psychiatric diseases, epilepsy, and disorders of consciousness. Both resting-state and task-based paradigms were identified, with perfusion studies being popular for detecting fast task-induced molecular connectivity changes. Metabolic connectivity, assessed via [18F]FDG-PET at rest, emerged as robust marker of functional integrity and disease progression, especially in neurodegenerative conditions. Multimodal PET/MRI studies revealed partial overlap between metabolic and hemodynamic connectivity. Noteworthy findings include the identification of default mode network through the study of CBF and disease-related covariance patterns in neurodegenerative disorders through the study of glucose metabolism. Integrating macroscale molecular brain organization studies with neurophysiological techniques will deepen the understanding of brain connectivity in health and disease. Additionally, total-body PET/MRI data may in the future elucidate brain-body interactions fostering a more comprehensive connectome framework.

#5

Glymphatic System Dysfunction in Central Nervous System Diseases.

CNS neuroscience & therapeutics2026 Mar

The glymphatic system is a perivascular cerebrospinal fluid (CSF)-interstitial fluid (ISF) exchange pathway that supports brain homeostasis by clearing metabolic waste and neurotoxic proteins. Across central nervous system diseases, converging evidence indicates that glymphatic dysfunction represents a shared pathophysiological axis linking vascular, astroglial, inflammatory, and sleep-related disturbances to impaired solute clearance. In this review, we synthesize mechanistic and clinical evidence for glymphatic impairment in acute brain injury (ischemic and hemorrhagic stroke, traumatic brain injury) and chronic neurological disorders (Alzheimer's disease, Parkinson's disease, cerebral small vessel disease, multiple sclerosis, idiopathic normal pressure hydrocephalus, idiopathic intracranial hypertension, epilepsy, and headache disorders). Major mechanisms include (i) aquaporin-4 (AQP4) depolarization/mislocalization at astrocytic endfeet, reducing perivascular water transport; (ii) perivascular space compression or obstruction from cytotoxic/vasogenic edema, blood-derived products, protein aggregates, or altered extracellular matrix; (iii) loss of arterial pulsatility and vascular stiffening, weakening the driving forces for convective exchange; (iv) blood-brain barrier disruption and neuroinflammation, which remodel perivascular architecture and amplify clearance failure; and (v) sleep and autonomic dysregulation, including altered noradrenergic tone, which suppresses glymphatic activity during periods when clearance is normally maximal. Clinically, glymphatic dysfunction can be probed using diffusion tensor imaging-analysis along the perivascular space (DTI-ALPS), contrast-enhanced MRI approaches, and structural surrogates such as enlarged perivascular spaces, with emerging associations to cognition, mood, and disease severity. Finally, we discuss translational strategies aimed at restoring clearance, including sleep/circadian optimization, vascular risk control, anti-inflammatory approaches, AQP4- and TRPV4-oriented targets, and neuromodulation. Mechanism-guided, standardized imaging and longitudinal interventional studies are needed to establish glymphatic biomarkers as actionable therapeutic and prognostic tools.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1 artigos no totalmostrando 200

2026

Identification of common genetic and molecular signatures in migraine and comorbid conditions.

The journal of headache and pain
2026

A patient with a rare metabolic disease and myo-inositol administration leading to a new treatment for epilepsy.

Molecular genetics and metabolism
2026

Pathophysiological roles of neural stem cells in neuropsychiatric diseases: from plasticity to pharmacological targeting.

Acta pharmacologica Sinica
2026

Glymphatic system dysfunction in epilepsy: a review of mechanisms and clinical evidence.

Encephalitis (Seoul, Korea)
2026

Impact of compound heterozygous SDHA variants on mitochondrial function in pediatric with neurological disease.

Mitochondrion
2026

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology
2026

Molecular mechanisms underlying the ferroptosis-induced epileptiform activity in mouse cortical slices.

Frontiers in cellular neuroscience
2026

Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial.

BMJ open
2026

Diagnostic reassessment in patients previously diagnosed with childhood-onset epilepsy during the transition to adult care: A retrospective cohort study in a tertiary epilepsy center.

Epilepsia open
2026

Primary Adrenal Insufficiency in Pseudo-Neonatal Adrenoleukodystrophy Case Report.

Journal of clinical research in pediatric endocrinology
2026

Molecular connectivity studies of cerebral glucose metabolism and blood flow: A scoping review.

Neuroscience and biobehavioral reviews
2026

Glymphatic System Dysfunction in Central Nervous System Diseases.

CNS neuroscience & therapeutics
2026

α-asaronol alleviates seizures, neuroinflammation and cognitive deficits in a mice model of lithium-pilocarpine-induced seizures.

Journal of ethnopharmacology
2026

Etiological Analysis and Classification of 108 Patients with Infantile Epileptic Spasms Syndrome Based on the 2017 International League Against Epilepsy Classification.

Noro psikiyatri arsivi
2026

Insulin Resistance as a Shared Pathophysiological Driver in Neurological Disorders: a Narrative Review.

Current nutrition reports
2026

Physiological Regulatory Mechanisms of Neurovascular Coupling and the Role of Its Dysfunction in Neurological Diseases.

Journal of integrative neuroscience
2026

The Citric Acid Cycle Modulates Neurologic Health and Is a Therapeutic Target of Dietary and Genetic Modification in Metabolic Disease.

Genes
2026

Myoclonus in Pediatric Metabolic Diseases: Clinical Spectrum, Mechanisms, and Treatable Causes-A Systematic Review.

Metabolites
2026

Continuing education course on genetic epilepsies was held by the Chilean society of epileptology.

Epileptic disorders : international epilepsy journal with videotape
2026

Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation.

Diabetes research and clinical practice
2026

mtDNA leakage promotes neuron-glia crosstalk to induce epilepsy by cGAS-STING-driven neuroinflammation and serine metabolic reprogramming.

Proceedings of the National Academy of Sciences of the United States of America
2026

Cardiovascular and bone health comorbidities in epilepsy.

Current opinion in neurology
2026

EEG, clinical, and MRI features of status epilepticus associated with mitochondrial diseases.

Journal of neurology
2026

Impact of Early Intervention on the Developmental and Ocular Outcome of Patients With Cobalamin C Deficiency Identified Through Newborn Screening.

Journal of inherited metabolic disease
2026

Arterial spin labeling reveals cerebral perfusion changes associated with involuntary movements in acute encephalopathy with biphasic seizures and late reduced diffusion: A case report.

Brain & development
2026

Adverse events and tolerability of ketogenic diets - a systematic literature analysis.

BMC nutrition
2026

Ketogenic diet sex-dependent effects on rat bone marrow cells during development and β-HB protection in hypoglycemia.

Scientific reports
2026

AAV-mediated gene therapy in a SLC13A5 citrate transporter disorder model rescues epileptic and metabolic phenotypes.

The Journal of clinical investigation
2026

Decoding the brain's ATG8 paralog code: LC3-GABARAP specialization at synapses and the astrocyte-neuron interface.

Frontiers in cell and developmental biology
2026

Association of atherogenic index of plasma and post-stroke epilepsy in patients with ischemic stroke: a multicenter retrospective study in China.

Therapeutic advances in neurological disorders
2026

Intrauterine exposure to maternal diabetes and the risk of developing epilepsy in children: a national cohort study of 2.3 million children.

BMC medicine
2026

Expanding the Phenotypic Spectrum of NDUFS6-Related Disease: From Neonatal Mitochondrial Encephalopathy to Childhood-Onset Axonal Neuropathy.

International journal of molecular sciences
2026

The associations between epilepsy, metabolism, and their clinical implications.

Frontiers in endocrinology
2026

Identifying the shared genes and their related microRNAs, metabolites, and pathways in ischemic stroke and epilepsy.

Scientific reports
2026

The neuropathological mechanisms underlying the inborn errors of lysine metabolism.

Neurobiology of disease
2026

Oligodendrocyte: Development, Plasticity, Biological Functions, Diseases, and Therapeutic Targets.

MedComm
2026

NMR metabolomic profiling of cerebrospinal fluid from dogs with meningoencephalitis of unknown origin demonstrates metabolic similarities to multiple sclerosis.

Metabolomics : Official journal of the Metabolomic Society
2026

Navigating the Ethereal Tightrope: The Nanogenerator Manipulates Neurons for Immune Equilibrium.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Validation of a Pediatric Cognitive Assessment Tool to Advance Knowledge on Children's Cognitive Development, Health Risk Factors, and Health-promoting Interventions in Sub-Saharan Regions.

Innovations in clinical neuroscience
2026

The immunoproteasome as a neuroimmune hub in the central nervous system: from proteostasis stress to inflammatory pathology.

Journal of neuroinflammation
2026

In search of "what really matters": Insights from a web-based survey on Patient-Centered Outcomes in GLUT1DS.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2026

Incident and prevalent peripartum mental illness in mothers with multiple sclerosis and other chronic diseases in Sweden.

Multiple sclerosis and related disorders
2026

Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.

British journal of clinical pharmacology
2026

Maternal Diabetes and Risk of Epilepsy in Offspring.

Pediatrics
2026

Dysfunction of GABAergic interneurons underlies altered neural network oscillations associated with epileptiform activity in PPT1-deficient mice.

Translational psychiatry
2026

Association of allostatic load with frailty trajectories and the mediating role of depressive symptoms.

The Journal of frailty & aging
2026

Long-term neurological outcome after hematopoietic stem cell transplant in juvenile Krabbe disease.

Journal of neurology
2026

Atypical Histopathological Findings in an Epilepsy Surgery Case of Sturge-Weber Syndrome With Coexisting Developmental Venous Anomaly.

Neuropathology : official journal of the Japanese Society of Neuropathology
2026

Towards Simplification of Ketogenic Diet in Epilepsy: Effect of Caprylic (C8) and Capric (C10) Acid on the Mitochondrial Respiratory Chain in Murine Hippocampal Neurons In Vitro.

Nutrients
2026

Network Hypoactivity in ALG13-CDG: Disrupted Developmental Pathways and E/I Imbalance as Early Drivers of Neurological Features in CDG.

Cells
2026

A CNS-Directed, AAV9 Gene Therapy Restores Expression and Biochemical Function of Guanidinoacetate Methyltransferase in Models of GAMT Deficiency.

International journal of molecular sciences
2026

A Rare Intruder: Neonatal Meningoencephalitis by Edwardsiella tarda Requiring Systemic and Intrathecal Antibiotics and Repeated Neurosurgery.

Antibiotics (Basel, Switzerland)
2026

Sodium Correction Rates and Associated Outcomes Among Patients With Severe Hyponatremia : A Retrospective Cohort Study.

Annals of internal medicine
2026

Natural History and Prognostic Factors in Pediatric Alexander Disease: A Cohort Study.

Pediatric neurology
2026

A rare GCH1 p.Arg170Gly variant shows impaired enzymatic activity and co-occurs with a novel NEXMIF p.Asp155GlnfsTer2 leading to a complex neurological phenotype: functional studies and clinical aspects.

Molecular genetics and metabolism
2026

A novel de novo RNF13 variant in developmental and epileptic encephalopathy 73: genotype-phenotype correlation and literature review.

BMC neurology
2026

Zinc and Copper Metallic Instability: Investigating Altered Metal Functionality in both Human and Animal Studies.

Biological trace element research
2026

Mimics and Diagnostic Pitfalls of Anti-Adenylate Kinase 5 Limbic Encephalitis.

CNS neuroscience & therapeutics
2026

Clinical characteristics, risk factors, and prognostic modeling for poor outcomes in children with influenza-associated encephalopathy: A retrospective cohort study.

Medicine
2026

ADK deficiency without hypermethioninemia presenting as intractable epilepsy: a rare neurometabolic case and literature review.

Neurogenetics
2026

Multisequence MRI Enables High-Fidelity FDG-PET Synthesis for Epilepsy Using GANs.

Journal of magnetic resonance imaging : JMRI
2026

Frameshift variants in the UBTF gene are associated with neurodevelopmental disorders.

Clinica chimica acta; international journal of clinical chemistry
2026

Recurrent hypocalcaemic seizures: diagnosing 22q11.2 deletion syndrome in early adulthood.

BMJ case reports
2026

Metabolomics-Driven Integration of Traditional Chinese Medicine for Neurological Disorders: From Precision Diagnosis to Therapeutic Innovation.

Phytotherapy research : PTR
2025

Modulation of Gut Microbiome and Metabolome as One of the Potential Mechanisms of Ketogenic Diet Effect in the Treatment of Epilepsy.

Nutrients
2026

Neuroimmune Regulation by TRPM2 Channels.

Cells
2026

Current neonatal seizure classification and approach to the newborn with seizure.

Proceedings (Baylor University. Medical Center)
2026

A mouse model of a patient derived P544L mutation in the Slc6a8 gene shows hypoactivity and cognitive deficits.

Brain research
2026

Hydroalcoholic extract of Benincasa hispida (Thunb.) Cogn. reinstates renal structural and functional dynamics compromised in diabetic mice: molecular insights through integration of transcriptomics and proteomics.

Journal of ethnopharmacology
2026

Primary oculoleptomeningeal transthyretin amyloidosis with subarachnoid hemorrhages, visual loss, and heart and skin amyloid deposits.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

First Reported Case of CLN5 Disease in Japan: Identification of a Novel Homozygous Pathogenic Variant Through Whole Genome Sequencing.

Clinical case reports
2025

An Emerging Role for OGDHL: From Mitochondrial Energy Metabolism to Neurodevelopmental Disorders.

Biology
2025

Fahr syndrome associated with hypoparathyroidism: Case report.

Medicine
2026

Hepatocellular Carcinoma: A Critical Complication in Patients Treated with Pyridoxal Phosphate.

Neuropediatrics
2025

Neurological, metabolic and inflammatory phenotypes in a mouse model of ECHS1 deficiency.

Brain communications
2025

Topiramate-induced distal renal tubular acidosis presenting as critical hypokalaemia.

BMJ case reports
2025

Gut microbiota-bile acid metabolic disorder involved in the cognitive impairments in epilepsy through HO-1 dependent ferroptosis.

Journal of pharmaceutical analysis
2025

Association of metabolic disorders and lifestyle behaviors with epilepsy: Evidence from the NHANES database.

Medicine
2025

Ammonia reduces glutamine synthetase expression in astrocytes via activation of Hippo-YAP signaling pathways.

Communications biology
2025

Impact of High-Dose Tafamidis on Hereditary ATTR (ATTRv) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up.

Journal of the peripheral nervous system : JPNS
2025

Juvenile/adult-onset POLG-related disease unmasked by valproate-associated fulminant hepatic failure.

BMJ case reports
2025

Gastrointestinal symptoms in neuronal ceroid lipofuscinoses (NCLs): an observational study on prevalence, timing of progression, and impact on quality of life.

Neurogenetics
2025

SLC35A2-Related Brain Disorders: Genetics, Pathophysiology, and Therapeutic Insights.

International journal of molecular sciences
2026

Astrocytes differentiated from patient iPSCs model the rare leukodystrophy MLC and uncover disease-linked maturation defects and Kir4.1 channel dysfunction.

Neurobiology of disease
2026

Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.

Neurology
2025

Revealing Monogenic Diabetes: Clinical and Genetic Features of Pediatric MODY Cases in Türkiye: Single Center Experience.

Pediatric diabetes
2025

Case Report: Congenital neurosyphilis presenting as post-hemorrhagic hydrocephalus in a preterm infant and a review of literature.

Frontiers in pediatrics
2025

Alterations in serum metabolomics predict drug-resistant epilepsy.

Scientific reports
2026

Untargeted Metabolomics for Diagnosis, Monitoring, and Understanding the Pathophysiology of Inherited Metabolic Disorders.

Journal of inherited metabolic disease
2025

Dysfunctional LHX6 pallido-subthalamic projections mediate epileptic events in a mouse model of Leigh syndrome.

The Journal of clinical investigation
2025

MRI-DTI Biomarkers Along the Continuum of Behavioral Variant Frontotemporal Dementia.

European journal of neurology
2025

A multicenter study on clinico-epidemiological profile of phenylketonuria in Egyptian children.

Scientific reports
2025

Neurological manifestations and clinical outcomes in pediatric Alexander disease: single-center cohort and identification of novel GFAP variants.

Brain & development
2025

Intranasal Liposomal Trimetazidine Nanocarriers Modulate Neuroinflammation and Neurotransmission via the HMGB1/TLR4/NF-κB Pathway in an Experimental Epilepsy Model.

Molecular neurobiology
2026

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial.

EBioMedicine
2025

Clinical analysis of non-ketotic hyperglycemia with reversible cortical blindness: a case report.

Journal of medical case reports
2025

Chromothriptic Translocation t(1;18): A Paradigm of Genomic Complexity in a Child with Normal Intellectual Development and Pyridoxine-Dependent Epilepsy.

Genes
2025

Investigating the neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies.

Nature communications
2026

Functional consequence of pathogenic GABRA3 variants determines whether X-linked inheritance is dominant or recessive.

The Journal of clinical investigation
2025

The Genotypic and Phenotypic Spectrum of GOSR2 Mutations: Clinical and Pathophysiological Insights.

Journal of inherited metabolic disease
2026

Longitudinal Characterization of Males With X-Linked Creatine Transporter Deficiency: Final Results of a Multiyear Observational Study.

Pediatric neurology
2026

Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.

Epilepsia
2026

Prominent U-waves without QT prolongation in X-linked creatine transporter deficiency caused by SLC6A8 variants.

Heart rhythm
2025

Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Neurology
2026

Oxidative stress and neuronal alteration: Mitochondrial dysfunction as a key player in intractable epilepsy - a narrative review.

Pathology, research and practice
2025

Liver Involvement in POLG Disease-a Multicentre Cohort Study of 202 Patients.

Journal of inherited metabolic disease
2025

The interplay between metabolism and neuroinflammation in epilepsy: mechanisms and therapeutic perspectives.

Journal of neuroinflammation
2025

Transition towards healthcare 'net zero': modelling condition-specific patient travel carbon emission estimations by transport mode in a retrospective population-based cohort study, Greater Glasgow, UK.

BMJ open
2025

The Gaucher Earlier Diagnosis Consensus point-scoring system for children and young adults: a retrospective and prospective evaluation in Korea.

Orphanet journal of rare diseases
2026

Interrogating Physiological Functions with Light and Chemicals.

Annual review of physiology
2025

Rethinking parvalbumin: From passive marker to active modulator of hippocampal circuits.

IBRO neuroscience reports
2025

Persistent lymphopenia in a Japanese boy with neuronal ceroid lipofuscinosis type 3.

European journal of medical genetics
2025

Sturge-Weber Syndrome Without Cutaneous Stigmata Versus Encephalocraniocutaneous Lipomatosis Without Craniocutaneous Lipomatosis: A Case Report.

WMJ : official publication of the State Medical Society of Wisconsin
2025

Lysine α-ketoglutarate reductase as a therapeutic target for saccharopine pathway related diseases.

Frontiers in molecular neuroscience
2025

Beyond Impaired GABAergic Signaling: Inflammation and Metabolic Dysfunction in Genetic Epilepsy Induced by GABRG2 Mutation.

Molecular neurobiology
2025

Congenital disorder of glycosylation type IIb in an infant with developmental and epileptic encephalopathy.

BMJ case reports
2026

Sex differences in clinical and prognostic trajectories in patients with idiopathic REM sleep behavior disorder: Insights from the FARPRESTO cohort.

Journal of Parkinson's disease
2025

Mechanistic role of gliflozins-induced ketosis in epileptogenesis and epilepsy: Rubric known and unknown.

Neuroscience
2026

Atypical clinical manifestation of MT-TL1 mutation in 6 months old patient.

Acta neurologica Belgica
2025

Predicting oxcarbazepine-induced hyponatremia in adult epilepsy patients: A multicenter machine learning analysis using real-world CDM data.

Seizure
2026

Feline neurological disease in a veterinary referral hospital in the UK: clinical diagnosis, neuroanatomical localisation and VITAMIN D-based aetiological distribution.

Journal of feline medicine and surgery
2025

Targeting AASS alleviates neurotoxicity and improves mitochondrial function in astrocyte models for pyridoxine-dependent epilepsy.

Molecular therapy. Nucleic acids
2026

Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency.

Movement disorders : official journal of the Movement Disorder Society
2025

Hypophosphatemia in suspected seizures evaluated in first seizure clinics and neurology consults.

Epilepsia open
2025

ATP6AP2-Related Disease Caused by Splicing Defects: Abnormal Glycosylation and the First Affected Female.

Journal of inherited metabolic disease
2025

GLUT1DS: focus on motor profile.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Metabolic reprogramming in diabetes and other endocrine and metabolic disorders: exploring the Warburg effect, ketones, and SGLT2 inhibitors.

Reviews in endocrine & metabolic disorders
2025

Pathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function.

Nature genetics
2025

Proteome-Wide Mendelian Randomization Reveals Novel Protein Targets for Epilepsy.

Current neuropharmacology
2026

siRNA for REST ameliorates symptoms in ALS mice and serum REST predicts disease prognosis and survival in ALS patients.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Protein glycosylation and synaptic transmission: brain glycogen keeps them separated.

Brain : a journal of neurology
2025

Prevalence and risk factors of seizures in cerebral amyloid angiopathy.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
2025

Advancing Understanding of Epilepsy and Type 1 Diabetes Mellitus: A Global Perspective on Research Trends and Future Directions.

Journal of diabetes research
2026

A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series.

Annals of clinical and translational neurology
2025

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2026

Partial substitution of ketogenic diet therapy with a blended diet: Evaluation of clinical practice in neurologically impaired fully tube fed children.

Nutrition (Burbank, Los Angeles County, Calif.)
2025

A Complex Case of Koolen-De Vries Syndrome Associated with Hypopituitarism and Type 1 Diabetes Mellitus.

Acta medica portuguesa
2025

Insights into ALG3-CDG: A case study combining glycan profiling and genetic analysis.

Molecular genetics and metabolism reports
2025

Biallelic ACSF3 variants with combined malonic and methylmalonic acidemia and associated developmental epileptic encephalopathy phenotype: A novel genotype-phenotype correlation.

Seizure
2025

Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum.

Neurology
2025

Palliative Care Approach in a Case of Severe Nonketotic Hyperglycinemia With Long Survival: A Case Report.

Cureus
2025

Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulation.

Movement disorders : official journal of the Movement Disorder Society
2025

Allopurinol Treatment Improves Cognitive Skills, Adaptive Behavior, and Biochemical Markers in Young Patients With Adenylosuccinate Lyase Deficiency.

Journal of inherited metabolic disease
2026

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals.

Clinical pharmacology and therapeutics
2025

In Vivo/In vitro metabolic profiling and evaluation of key metabolites of QO-83, a novel KCNQ channel opener with antiepileptic potential.

Biochemical pharmacology
2025

Molecular deconstruction of the pre-Bötzinger Complex/Nucleus Ambiguus (preBötC/NA) region: cellular constituencies and transcriptional responses to repeated seizures in the rat hindbrain.

bioRxiv : the preprint server for biology
2025

[Immunity and epilepsy. Autoimmune encephalitis and epilepsy linked to autoimmune disorders].

Medicina
2025

Pharmacological Diversity of Flavonoids and Their Clinical Application Prospects in Neurological Disorders.

Phytotherapy research : PTR
2025

Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome.

Epileptic disorders : international epilepsy journal with videotape
2025

Screening of metabolic markers in pediatric epilepsy disorders.

Journal of translational medicine
2025

Epileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication.

Materials today. Bio
2025

A GABRB3 mutation (c.5G>A, p.Trp2*) in twins with generalized epilepsy with febrile seizures: A case report.

Experimental and therapeutic medicine
2025

The burden of comorbidities and comedication in adults with epilepsy.

Epilepsy & behavior : E&B
2025

The Ketogenic Diet Through a Metabolomic Lens: Biochemical Pathways, Therapeutic Applications, and Analytical Challenges.

Nutrients
2025

Voltage-Gated Sodium Channel Dysfunction in Epilepsy: Zebrafish Models for Therapeutics.

Biomedicines
2026

Children With Pancreatic Hypoplasia Experience Poor Weight Gain and Labile Diabetes but Low Incidence of DKA.

The Journal of clinical endocrinology and metabolism
2025

Neurovascular Pathophysiology and Emerging Biomarkers in Cerebral Malaria: An Integrative Perspective.

Neurology international
2025

Comprehensive genotypic, phenotypic, and biochemical characterization of GOT2 deficiency: A progressive neurodevelopmental disorder with epilepsy and abnormal movements.

Genetics in medicine : official journal of the American College of Medical Genetics
2025

Severe non-diabetic ketoacidosis due to starvation and Graves' disease.

BMJ case reports
2025

Individual lipid alterations at the origin of neuronal Ceramide Synthase defects.

PLoS genetics
2026

Sport Activities for Children and Adolescents: Part 2. Joint Position Statement of Paediatric Societies on Physical Activity and Sport Recommendations for Children With Specific Chronic Disease Conditions.

Acta paediatrica (Oslo, Norway : 1992)
2025

Epileptic seizures associated with denosumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2026

CLN2 Disease: Current Understandings, Challenges, and Future Directions.

Journal of child neurology
2025

[Clinical characteristics analysis of mitochondrial short-chain enoyl-CoA hydratase 1 deficiency with ECHS1 gene c.489G>A compound heterozygous variants].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

Genetic association and potential mediators between subjective well-being and cardiovascular events: A bidirectional two-sample, two-step Mendelian randomization study.

Medicine
2025

Seizures and hypoparathyroidism post-thyroidectomy: Fahr's syndrome.

BMJ case reports
2025

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Neurology
2025

Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndrome.

The Journal of clinical investigation
2025

Astrocyte Lipid Droplet Dynamics Orchestrate Neurological Disorders and Therapeutic Horizons.

Small science
2025

Intracranial calcifications in congenital viral infections: mechanisms and cellular roles.

Current opinion in virology
2025

Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2025

Genetic disorders of dolichol synthesis and utilization.

Molecular genetics and metabolism
2025

Cerebral Palsy Associated With Neonatal Encephalopathy: Review of Te Rēhita a Hōkai Nukurangi Aotearoa-The New Zealand Cerebral Palsy Register (NZCPR) Data.

Journal of paediatrics and child health
2025

[Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cerebrovascular accidents].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Neonatal diabetes mellitus is a significant feature of COXPD-24 caused by recessive NARS2 variants.

Diabetic medicine : a journal of the British Diabetic Association
2025

Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome associated with alteration of metabolic signaling.

American journal of human genetics
2025

The use of synaptic extracellular myo-inositol to treat Developmental and Epileptic Encephalopathy.

Annals of the Child Neurology Society
2025

Beyond Seizures: A Comprehensive Review of Giant Somatosensory Evoked Potentials.

Journal of clinical medicine
2025

Sleep Disorders in Infants and Toddlers with Hypoxic Ischemic Encephalopathy Treated with Therapeutic Hypothermia: A Case-Control Study Using the SDSC.

Children (Basel, Switzerland)
2025

Recent insights into the implications of UGDH mutations for human developmental disease.

Biochemical Society transactions
2025

Selective muscle MRI changes in a patient with a rare mitochondrial DNA variant causing myoclonic epilepsy with ragged red fibres.

Neuromuscular disorders : NMD
2025

Advancing Neonatal Screening for Pyridoxine-Dependent Epilepsy-ALDH7A1 Through Combined Analysis of 2-OPP, 6-Oxo-Pipecolate and Pipecolate in a Butylated FIA-MS/MS Workflow.

International journal of neonatal screening
2025

Exploration of autophagy-related molecular mechanisms underlying epilepsy using multiple datasets.

The Journal of international medical research
2025

Cardiovascular disease and microbiome: focus on ischemic stroke.

Polish archives of internal medicine
2025

[Clinical characteristics and efficacy of glyceryl phenylbutyrate treatment in 20 pediatric patients with urea cycle disorder].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

The homoplasmic MT-TK m.8357T > C mtDNA variant as a cause of multiorgan mitochondrial disease.

Mitochondrion
2025

Co-morbid seizures in frontotemporal dementia: What do they tell us?

Epilepsy research
2025

Identification of three novel GNAO1 variants in a Chinese cohort with GNAO1 encephalopathy: expanding the clinical and genetic spectrum.

Orphanet journal of rare diseases
2025

Epilepsy and systemic autoimmune diseases: A bidirectional two-sample Mendelian randomization study.

Epilepsia open
2025

McLeod syndrome mimicking mitochondrial myopathy due to a novel in-frame duplication in the XK gene.

Neuromuscular disorders : NMD
2025

Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot-Marie-Tooth Disease.

Annals of neurology
2026

Neonatal hypoglycaemic brain injury, a common cause of early-childhood epilepsy in India: A prospective longitudinal study on aetiologies and outcomes.

Developmental medicine and child neurology
2026

Associations between epilepsy-related polygenic risk and brain morphology in childhood.

Brain : a journal of neurology
2026

Functional Characterization of Two Novel Biallelic PIGV Variants in a Patient With Myoclonic Seizures and Elevated Alkaline Phosphatase: A Case Report.

American journal of medical genetics. Part A
2025

Design considerations for C9orf72 disease prevention trials.

Brain : a journal of neurology
2025

Seizures and electroencephalographic findings in inborn errors of metabolism: Clues to differential diagnosis in the neonatal period, infancy, childhood and adolescence, and review of the literature.

Epileptic disorders : international epilepsy journal with videotape
2025

First clinical diagnosis of FAME3 via commercial Long-Read sequencing reveals mosaic repeat expansion in MARCHF6 gene.

Neurogenetics
2025

Cognitive dysfunction in systemic lupus erythematosus: A pilot study on the role of serum neuron-specific enolase levels.

Lupus

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doenças metabólicas com epilepsia.

É de uma associação que acompanha esta doença? Fale com a gente →

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

Não há uma cura universal estabelecida para este grupo de doenças metabólicas nos registros médicos oficiais. O tratamento visa ao manejo clínico das crises epilépticas e à correção das manifestações metabólicas específicas de cada diagnóstico.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

3 fontes citadas no texto · 10 publicações do grafo RarasNet (PubMed) · 4 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. MONDO
    purl.obolibrary.org
  2. Epilepsia
    PCDT · Ministério da Saúde
  3. Q55785632
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (2026). Doenças metabólicas com epilepsia. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doencas-metabolicas-com-epilepsia

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doenças metabólicas com epilepsia

ORPHA:166481 · MONDO:0015656
🇧🇷 Brasil SUS
Geral
MedGen
UMLS
C1299598
Repurposing
14 candidatos
aminohydroxybutyric-acid — carbonic anhydrase inhibitor
diclofenamide — succinimide antiepileptic
ethosuximide — glutamate receptor antagonist
+11 outros
EuropePMC
Wikidata

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Dado público estruturado
fonte: Wikidata
Rara